Effect of Black garlic consumption on treatment of non-alcoholic fatty liver disease

Evaluating the effect of black garlic on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201204049599N6

Enrollment

Registered

2022-10-26

Start date

2022-11-05

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: In the intervention group, in addition to the usual treatment, will be recommended to consume 6 grams of black garlic in total per day before morning and evening me

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age older than 18 years old from both sexes BMI more than 30 Patients with non-alcoholic fatty liver disease diagnosed through ultrasound and referred to Imam Hospital Gastroenterology Clinic

Exclusion criteria

Exclusion criteria: Special diets Pregnancy and lactation during the study Viral hepatitis Alcohol consumption or history of alcohol consumption Non-compliance to our recommendations regarding Black garlic consumption Untreated hypothyroidism Renal diseases Taking drugs that increase liver enzymes Alpha antitrypsin deficiency Gastrointestinal disease such as celiac disease Menopause Diabetes mellitus Herbal therapy Heart failure and bone disease

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: At weeks 0, 12. Method of measurement: Scale, kg.;Body mass index. Timepoint: At weeks 0, 12. Method of measurement: Weight(kg)/[height(m)]2 , kg/m2.;Gamma Glutamyl transferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method , IU/ Lit.;Alkalin Phosphatase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method , IU/ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/Lit.;Alanine Aminotransferase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Fasting blood sugar. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Waist circumference. Timepoint: At weeks 0, 12. Method of measurement: Cm.;Hepatic steatosis. Timepoint: Before intervention and three month after intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;HOMA-IR. Timepoint: At weeks 0, 12. Method of measurement: Formula.;Height. Timepoint: Before intervention. Method of measurement: Stadiometer, mm.	—

Measure

Time frame

Weight. Timepoint: At weeks 0, 12. Method of measurement: Scale, kg.;Body mass index. Timepoint: At weeks 0, 12. Method of measurement: Weight(kg)/[height(m)]2 , kg/m2.;Gamma Glutamyl transferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method , IU/ Lit.;Alkalin Phosphatase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method , IU/ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/Lit.;Alanine Aminotransferase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Fasting blood sugar. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/ Lit.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Waist circumference. Timepoint: At weeks 0, 12. Method of measurement: Cm.;Hepatic steatosis. Timepoint: Before intervention and three month after intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;HOMA-IR. Timepoint: At weeks 0, 12. Method of measurement: Formula.;Height. Timepoint: Before intervention. Method of measurement: Stadiometer, mm.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Pashaei

Oroumia University of Medical Sciences

pashaee.m@umsu.ac.ir+98 44 3346 9931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026